Select Page

Cost-Benefit Analysis of ‘Breakthrough’ Cancer Drugs

Oct 30, 2019

Highlights In the current landscape of high costs of cancer treatment, many FDA and EMA approved cancer drugs entered the market based on surrogate end-points, without evidence of benefit on overall survival or quality of life, as reported by clinical studies...